Investment Analysts’ Weekly Ratings Changes for Amgen (AMGN)

Several analysts have recently updated their ratings and price targets for Amgen (NASDAQ: AMGN):

• 5/5/2026 – Amgen had its “hold” rating reaffirmed by Erste Group Bank AG.
• 5/4/2026 – Amgen had its price target lowered by Guggenheim from $351.00 to $340.00. They now have a “neutral” rating on the stock.
• 5/1/2026 – Amgen was given a new $332.00 price target by Morgan Stanley.
• 5/1/2026 – Amgen had its price target raised by Truist Financial Corporation from $325.00 to $327.00. They now have a “hold” rating on the stock.
• 5/1/2026 – Amgen had its price target raised by The Goldman Sachs Group, Inc. from $415.00 to $425.00. They now have a “buy” rating on the stock.
• 4/28/2026 – Amgen had its price target raised by Morgan Stanley from $309.00 to $326.00. They now have an “equal weight” rating on the stock.
• 4/25/2026 – Amgen was downgraded by Wall Street Zen from “buy” to “hold”.
• 4/20/2026 – Amgen is now covered by Canaccord Genuity Group Inc.. They set a “hold” rating and a $366.00 price target on the stock.
• 4/13/2026 – Amgen had its price target raised by UBS Group AG from $390.00 to $400.00. They now have a “buy” rating on the stock.
• 4/11/2026 – Amgen was upgraded by Wall Street Zen from “hold” to “buy”.
• 4/10/2026 – Amgen had its price target raised by Morgan Stanley from $309.00 to $326.00. They now have an “equal weight” rating on the stock.
• 4/9/2026 – Amgen had its price target raised by Guggenheim from $347.00 to $351.00. They now have a “neutral” rating on the stock.
• 4/8/2026 – Amgen had its “neutral” rating reaffirmed by Cantor Fitzgerald. They now have a $350.00 price target on the stock.
• 4/7/2026 – Amgen had its price target raised by Royal Bank Of Canada from $360.00 to $370.00. They now have an “outperform” rating on the stock.
• 3/19/2026 – Amgen had its price target raised by Wells Fargo & Company from $375.00 to $390.00. They now have an “equal weight” rating on the stock.
• 3/10/2026 – Amgen is now covered by Jefferies Financial Group Inc.. They set a “hold” rating and a $350.00 price target on the stock.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is 70.15%.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.85% of the company’s stock.

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.